| 查看: 710 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么？
|
|
西替利嗪用于儿童，不同资料说法不一：包括“不推荐用于6岁以下儿童”，“不推荐用于12岁以下儿童”，“2岁以下儿童禁用”，“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是？ 西替利嗪在儿童用药的主要风险是什么？ 希望有最新资料的站友给予解释 |
回复此楼» 猜你喜欢
售SCI-T0P文章，我:8O.5.5.1.O.54,科目齐全,可+急
已经有7人回复
-
售SCI一区T0P文章，我:8.O.55.1.O.5.4,科目全,可+急
已经有8人回复
-
售SCI一区T0P文章，我:8.O55.1.O.54,科目全,可十急
已经有15人回复
-
有多少人是今天查系统知道结果的？
已经有19人回复
-
国社科又开始会评了，不知道这次命运如何
已经有9人回复
-
能否申诉？
已经有5人回复
-
为什么到现在没收到通知？
已经有5人回复
-
有没有仍没收到信息的
已经有8人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有5人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有4人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 转：用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
- 【转帖】强生制药双阴影：召回局未了，质量门添忧
已经有0人回复
» 抢金币啦！回帖就可以得到:
-
面上中了，散金币。
+5/1610
-
云南大学丁军桥团队2027年博士招生
+1/947
-
八年奋战，面上中了，同时一个读了8年的博士（中途接手）答辩通过了，都是涉险过关
+2/388
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/96
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/96
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/95
-
东南大学能源与环境学院-林日琛教授课题组-27级博士招生
+1/92
-
原子层沉积（ALD）磁控溅射PECVD等微纳代工服务：18817872921
+1/92
-
很认可这句话
+1/84
-
今日少年明日老。
+1/83
-
2024级硕士求推荐博导-计算模拟背景
+3/47
-
深圳大学刘翼振课题组诚聘博士后（CRISPR分子诊断）
+1/44
-
北京师范大学（珠海）化学传感与成像课题组2026年研究生（统招/推免）招生
+1/13
-
中国科学院广州生物医药与健康研究院课题组招收博士研究生1名（2027年9月入学）
+1/8
-
香港大学智能制造实验室招收27年春秋季入学全奖博士和硕士研究生
+1/5
-
2026年工程管理与智慧城市国际会议 (EMSC 2026)
+1/4
-
项目助理招聘启事
+1/2
-
复旦大学博士招生：Micro-LED光互连芯片设计（2026年11月截止）
+1/1
-
专利审查意见答复，是AI辅助生成中很难的一个功能...
+1/1
-
寻求合作【出版代理】兼职推广｜无需坐班｜一单5000元
+1/1
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料，显示对6个月以上儿童进行过安全性评价，应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复，贴到这，与同道共享 |
4楼2011-07-14 10:35:31
